Trials / Recruiting
RecruitingNCT06295770
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Obinutuzumab | Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6. |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-03-06
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06295770. Inclusion in this directory is not an endorsement.